Burden of Visceral Leishmaniasis in Villages of Eastern Gedaref State, Sudan: An Exhaustive Cross-Sectional Survey

listen audio

Study Justification:
– The study aimed to estimate the incidence of visceral leishmaniasis (VL) in villages around Tabarak Allah Hospital in eastern Gedaref State, Sudan.
– Médecins Sans Frontières has been treating VL patients in this area since 2009, and the study aimed to gather data to better understand the burden of VL in the region.
– The study also aimed to assess the effectiveness of active VL case detection as an intervention for controlling VL in similar contexts.
Highlights:
– The study conducted an exhaustive door-to-door survey in 45 villages, interviewing 17,702 households and a population of 94,369 inhabitants.
– The crude mortality rate over the recall period was 0.13/10,000 people per day, with VL being a possible or probable cause for 19% of all deaths.
– The VL-specific mortality rate was estimated at 0.9/1000 per year.
– The overall incidence of VL over the past year was 7.0/1000 persons per year, or 7.9/1000 per year when deaths possibly or probably due to VL were included.
– The study found that active VL case detection had a very low yield in this specific setting with adequate access to care, suggesting it may not be the priority intervention for control in similar contexts.
Recommendations:
– Based on the study findings, the study recommends focusing on other interventions to enhance VL control in similar contexts, rather than solely relying on active case detection.
– Further research is needed to identify effective strategies for VL control in areas with adequate access to care.
Key Role Players:
– Médecins Sans Frontières
– Sudanese National Ministry of Health
– Gedaref Ministry of Health
– Head of villages
– Medical teams
Cost Items for Planning Recommendations:
– Training and capacity building for medical teams
– Supplies and equipment for diagnosis and treatment of VL
– Community education and awareness campaigns
– Monitoring and evaluation activities
– Coordination and collaboration with relevant stakeholders
– Research and data analysis

The strength of evidence for this abstract is 8 out of 10.
The evidence in the abstract is strong, but there are some areas for improvement. The study conducted an exhaustive door-to-door survey in 45 villages, interviewed 17,702 households, and collected data on a population of 94,369 inhabitants. The study also obtained ethical clearance and written authorization from relevant authorities, and obtained oral informed consent from participants. The study provides detailed information on the methods used, including the criteria for case ascertainment and the diagnostic tests used. However, the abstract could be improved by providing more information on the study design, such as whether it was a prospective or retrospective study, and by including information on the limitations of the study. Additionally, the abstract could provide more context on the significance of the findings and their implications for public health. To improve the evidence, the authors could consider providing more information on the sampling strategy used, the representativeness of the study population, and the generalizability of the findings. They could also discuss the potential biases and confounders that may have influenced the results. Overall, the evidence in the abstract is strong, but these suggestions could further enhance its quality.

Background: Since December 2009, Médecins Sans Frontières has diagnosed and treated patients with visceral leishmaniasis (VL) in Tabarak Allah Hospital, eastern Gedaref State, one of the main endemic foci of VL in Sudan. A survey was conducted to estimate the VL incidence in villages around Tabarak Allah. Methods: Between the 5th of May and the 17th of June 2011, we conducted an exhaustive door-to-door survey in 45 villages of Al-Gureisha locality. Deaths were investigated by verbal autopsies. All individuals with (i) fever of at least two weeks, (ii) VL diagnosed and treated in the previous year, and (iii) clinical suspicion of post-kala-azar dermal leishmaniasis (PKDL) were referred to medical teams for case ascertainment. A new case of VL was a clinical suspect with a positive rk39 rapid test or direct agglutination test (DAT). Results: In the 45 villages screened, 17,702 households were interviewed, for a population of 94,369 inhabitants. The crude mortality rate over the mean recall period of 409 days was 0.13/10’000 people per day. VL was a possible or probable cause for 19% of all deaths. The VL-specific mortality rate was estimated at 0.9/1000 per year. The medical teams examined 551 individuals referred for a history of fever of at least two weeks. Out of these, 16 were diagnosed with primary VL. The overall incidence of VL over the past year was 7.0/1000 persons per year, or 7.9/1000 per year when deaths possibly or probably due to VL were included. Overall, 12.5% (11,943/95,609) of the population reported a past VL treatment episode. Discussion and Conclusion: VL represents a significant health burden in eastern Gedaref State. Active VL case detection had a very low yield in this specific setting with adequate access to care and may not be the priority intervention to enhance control in similar contexts. © 2012 Mueller et al.

Ethical clearance was granted from the Sudanese National Ministry of Health’s Research Ethics Review Committee. Written authorization to conduct the study was obtained from the Gedaref Ministry of Health and each head of village. Each head of household provided oral informed consent to the collection of demographical data, history of VL treatment, skin rash after treatment, and presence of fever of at least two weeks among household members. A referral form was given for each individual presenting with fever of more than two weeks, with suspicion of PKDL or having been treated for VL in the last year. The information included in these forms was not identifying and individuals were free to reach or not the medical team for clinical investigation. An additional oral consent was obtained from clinical suspects before testing for VL. The choice of oral consent was made because of the low literacy rate in the study area and the unlikelihood to easily find an impartial literate witness for each household. The Sudanese National Ministry of Health’s Research Ethics Review Committee expressly approved the method of oral consent without use of a witness or written record of oral consent. Between the 5th of May and the 17th of June 2011, we conducted an exhaustive door to door survey in the 45 villages of Al-Gureisha locality, covering a population of about 85,000 inhabitants. The survey villages were grouped into four geographical areas. Each area was surveyed by four field teams and one medical team. Demographic information (age, sex, household composition on the day of survey and one year prior, number of births, deaths and movements within the past year) was collected by the field teams in each household. A household was defined as all people living together under the responsibility of one head of household and eating regularly together. For each household member, the history of VL treatment and possible subsequent PKDL was also recorded. The number and the causes of any death occurring in the past year were investigated in order to identify deaths possibly attributable to VL. Verbal autopsies were conducted for all reported deaths except for neonatal, delivery-related, and accidental deaths, as these were unlikely to be related to VL. Maternal deaths not directly related to delivery were investigated, as VL during pregnancy is known to be associated with increased treatment toxicity and mortality [12], [13]. Individuals with fever of at least two weeks duration, individuals diagnosed and treated for VL during the past year, and clinical suspects of either PKDL or VL relapse (independently of the time elapsed since treatment) were referred to the medical teams for clinical examination and case ascertainment. New clinical VL suspects (defined as fever for at least two weeks with at least one of the following: splenomegaly, lymphadenopathies or history of weight loss) were tested with an rK39 antigen-based rapid test (DiaMed IT-Leish) [14] and, if negative, with the direct agglutination test (DAT) [15], [16] for VL confirmation. A new VL case was defined as a clinical suspect who was confirmed either by the rK39 or the DAT. New VL cases, suspected VL relapses, and moderate and severe PKDL cases were referred to Tabarak Allah Hospital. Because of the self-healing nature of PKDL in Sudan and the potential toxicity of the recommended SSG treatment, mild PKDL cases were not offered SSG treatment [6] and therefore were not referred to Tabarak Allah Hospital. To estimate the incidence rates at the village level, the population was exhaustively screened. We calculated a sample size of 266 deaths to estimate a proportion of deaths due to VL of 30% with a 5% precision (alpha 0.05). Based on an expected total number of deaths around 1500 (corresponding to an annual mortality rate of 0.5/10’000 persons per day), we planned to investigate the cause of every fifth death through verbal autopsy, using a systematic sampling procedure. All deaths were recorded consecutively on a tally sheet, with the death to be investigated pre-highlighted. As the data collected during the first three weeks of the survey showed a number of deaths much lower than expected, we later conducted verbal autopsies for every reported death. The analysis of the causes of death was weighted accordingly. All verbal autopsies were reviewed independently by two clinicians experienced in VL and fluent in Arabic. In case of disagreement, the files were reviewed by a third expert clinician, with the help of a translator, and his verdict was final. Death was considered possibly due to VL if the respondent mentioned fever of at least two weeks duration and either one of the following: enlarged lymph nodes, a visible mass in the left upper part of the abdomen (spleen side), or weight loss, during the final illness of the deceased. Death was considered as probably due to VL if it occurred during treatment for VL (clearly mentioned by the relatives of the deceased) in a treatment facility offering reliable VL diagnosis (i.e. rk39 rapid test, DAT or microscopic examination of lymph node aspirate with quality control in place). If a death was reported to have occurred in another treatment facility during VL treatment, it was considered as possibly due to VL. The event chosen to define the start of the recall period (covering the past year) was the presidential elections in Sudan, which occurred on the 10th and 11th of April 2010. The average recall period (referred hereafter as the “the past year”) was therefore 409 days. The end of the sesame harvest (end of October 2010) was used to define a 6-month recall period. VL incidence rate over the period was calculated by summing the new VL cases detected during the survey, the VL cases and the deaths possibly/probably due to VL reported over the recall period, divided by the mid-year population. All documents were translated in Arabic and back-translated into English, and were subjected to pilot testing with subsequent update before the start of the survey. Data were entered in the EpiData software (EpiData, Odense, Denmark) by four data entry clerks. Data were analysed using the Stata 11 software (Stata Corporation, College Station, Texas, USA). Description of geographical information was performed using the QuantumGIS software, version 1.7.0. The coordinates of the Atbarah River were obtained by manually drawing along the river in Google Earth.

Based on the provided information, it is not clear how the study on the burden of visceral leishmaniasis in villages of Eastern Gedaref State, Sudan relates to innovations for improving access to maternal health. However, here are some potential recommendations for innovations that could be used to improve access to maternal health:

1. Telemedicine: Implementing telemedicine programs that allow pregnant women in remote areas to consult with healthcare professionals through video calls or phone calls. This can help provide prenatal care and address any concerns or complications without the need for travel.

2. Mobile clinics: Utilizing mobile clinics equipped with medical professionals and necessary equipment to reach rural areas and provide prenatal care, screenings, and basic healthcare services to pregnant women who may not have access to a nearby healthcare facility.

3. Community health workers: Training and deploying community health workers who can provide education, support, and basic healthcare services to pregnant women in their communities. These workers can also help identify high-risk pregnancies and refer women to appropriate healthcare facilities.

4. Maternal health vouchers: Implementing voucher programs that provide pregnant women with access to essential maternal health services, such as prenatal care, delivery, and postnatal care. These vouchers can be distributed to women in need and redeemed at participating healthcare facilities.

5. Mobile applications: Developing mobile applications that provide pregnant women with information, reminders, and guidance on prenatal care, nutrition, and healthy practices during pregnancy. These apps can also help women track their pregnancy progress and connect with healthcare professionals for virtual consultations.

6. Transportation solutions: Improving transportation infrastructure and implementing transportation solutions, such as ambulances or transportation subsidies, to ensure pregnant women can easily access healthcare facilities for prenatal care, delivery, and emergency obstetric care.

7. Maternal health clinics: Establishing dedicated maternal health clinics in underserved areas, staffed with skilled healthcare professionals who can provide comprehensive prenatal care, delivery services, and postnatal care.

It is important to note that these recommendations are general and may need to be adapted to the specific context and challenges faced in improving access to maternal health in Eastern Gedaref State, Sudan.
AI Innovations Description
Based on the provided information, the following recommendation can be developed into an innovation to improve access to maternal health:

1. Implement a comprehensive maternal health program in the villages of Eastern Gedaref State, Sudan, with a focus on preventing and treating maternal complications related to visceral leishmaniasis (VL).
2. Establish mobile medical teams that can provide regular antenatal care, including screening and treatment for VL, to pregnant women in the villages.
3. Train local healthcare providers on the identification, diagnosis, and management of VL in pregnant women, as well as the prevention of maternal deaths related to VL.
4. Improve access to VL diagnostic tests, such as the rk39 rapid test and direct agglutination test (DAT), in healthcare facilities in the villages.
5. Strengthen referral systems to ensure timely access to specialized care for pregnant women with VL or complications related to VL.
6. Raise awareness among community members, especially pregnant women and their families, about the signs and symptoms of VL and the importance of seeking early medical care.
7. Collaborate with local authorities and community leaders to address any cultural or social barriers that may hinder access to maternal healthcare services.
8. Monitor and evaluate the implementation of the maternal health program to assess its impact on reducing maternal mortality and improving access to care for pregnant women with VL.

By implementing these recommendations, it is expected that access to maternal health services will be improved, leading to a reduction in maternal mortality related to VL in the villages of Eastern Gedaref State, Sudan.
AI Innovations Methodology
To improve access to maternal health, here are some potential recommendations:

1. Telemedicine: Implementing telemedicine programs can provide remote access to healthcare professionals for prenatal care, consultations, and monitoring. This can be especially beneficial for women in rural or underserved areas who may have limited access to healthcare facilities.

2. Mobile clinics: Setting up mobile clinics that travel to remote areas can bring essential maternal health services directly to communities. These clinics can provide prenatal care, vaccinations, screenings, and education on maternal health.

3. Community health workers: Training and deploying community health workers can help bridge the gap between healthcare facilities and communities. These workers can provide education, support, and basic healthcare services to pregnant women, ensuring they receive the necessary care throughout their pregnancy.

4. Maternal health vouchers: Implementing voucher programs can help reduce financial barriers to accessing maternal health services. Vouchers can cover the cost of prenatal care, delivery, and postnatal care, making it more affordable for women to seek the care they need.

To simulate the impact of these recommendations on improving access to maternal health, a methodology could include the following steps:

1. Define the target population: Identify the specific population that would benefit from the recommendations, such as pregnant women in a particular region or community.

2. Collect baseline data: Gather data on the current access to maternal health services in the target population, including factors such as distance to healthcare facilities, availability of healthcare providers, and utilization rates.

3. Model the impact of recommendations: Use mathematical modeling techniques to simulate the potential impact of the recommendations on improving access to maternal health. This could involve estimating the number of additional women who would have access to care, the reduction in travel distance, or the increase in utilization rates.

4. Validate the model: Validate the model by comparing the simulated results with real-world data, if available. This can help ensure the accuracy and reliability of the simulation.

5. Sensitivity analysis: Conduct sensitivity analysis to assess the robustness of the model and explore different scenarios or variations in the input parameters. This can help identify potential limitations or uncertainties in the simulation results.

6. Evaluate cost-effectiveness: Assess the cost-effectiveness of implementing the recommendations by comparing the estimated impact on improving access to maternal health with the associated costs of implementing and maintaining the interventions.

7. Communicate findings: Present the simulation results and findings to relevant stakeholders, such as policymakers, healthcare providers, and community members. This can help inform decision-making and prioritize interventions to improve access to maternal health.

It’s important to note that the specific methodology may vary depending on the available data, resources, and context of the study.

Partilhar isto:
Facebook
Twitter
LinkedIn
WhatsApp
Email